1 Second International Biobanking Summit (IBS-II): Future Directions Alte Universität, Graz, Austria September 17, 2013 Big Data, Privacy Protection and Ethics Harmonisation Bartha M. Knoppers Director, Centre of Genomics and Policy Canada Research Chair in Law and Medicine McGill University
2 Outline Introduction: Big Data and Privacy Protection A Way Forward: The Global Alliance Towards International Interoperability: IPAC Conclusion: A Safe Harbour for Ethics Harmonisation?
3 Introduction: A World of Big Data What is Big Data? Datasets whose size are beyond the ability of typical database software tools to capture, store, manage and analyse. As technology advances over time, the size of datasets that qualify as Big Data will also increase. - McKinsey Global Institute: Big data: The next frontier for innovation, competition, and productivity (2011)
4 Introduction: A World of Big Data Data is the 21st century s new raw material. - Rt. Hon. Francis Maude - Open Data White Paper: Unleashing the Potential (UK, 2012)
5 Introduction: A World of Big Data A wealth of information creates a poverty of attention and a need to allocate that attention efficiently among the overabundance of information sources that might consume it. - Herbert Simon (1971)
6 Introduction: A World of Big Data Eric E. Schadt, The Changing Privacy Landscape in the Era of Big Data, Molecular Systems Biology 8, 612 (2012).
7 Introduction: A World of Big Data
8 Privacy Protection Big Data: Potential to create significant value for the world (in terms of innovation, productivity, economic benefit, health outcomes, etc.) but what about the risks to privacy and data protection? Big Data creates transparency, but at what cost to privacy?
9 Privacy Protection Privacy protection comes in two main forms 1. Laws, regulations and guidance EU: Data Protection Directive 95/46 EC Canada: PIPEDA, public/private/health sector statutes (prov.) U.S.: FTC s Fair Information Practice Principles OECD: Guidelines on the Protection of Privacy and Transborder Flows of Personal Data 2. Industry self-regulation Privacy Utility
10 Privacy Protection Six areas of concern in the age of Big Data: Informed consent Purpose specification Fair Information Practices Data minimization Binary of personal vs. non-personal data Effective anonymization/de-identification National privacy/data protection laws that unduly restrict transborder data flows Has Big Data changed the nature of risk to privacy?
11 Privacy Protection: Two Open Questions Should policymakers create exceptions in privacy/data protection laws for 1) certain research purposes (or a safe harbour approach application and approval structure administered by a central/federated authority?); and for 2) the use of anonymized or aggregated data? We can aim to ensure that all data is cleaned of identifiers before being transferred into large databases, but how sure are we the data is legally or truly de-identified?
12 Privacy Protection: Four Observations Privacy is an important value, but not an absolute value time to rethink some of the privacy principles listed in the OECD Privacy Guidelines There is a need to harmonize privacy/data protection laws across the globe in the long term, and in the short term, work towards interoperability of privacy/data protection laws, and give more focus to reforming/enacting anti-discrimination protections Recognize the limits of law and regulation (e.g. inflexibility) and embrace more Codes of Conduct We need to continue to support and develop new privacy-enhancing technologies (e.g. DataSHIELD) [W]e now need to understand what information is personally identifiable and to figure out collectively what reasonable expectation of privacy we have regarding such data. I believe education and legislation aimed less at protecting privacy and more at preventing discrimination will be key. Eric Schadt
13 Global Biomedical Research: Suffering from Silos and Insufficiencies
14 A Way Forward: The Global Alliance
15 A Way Forward: The Global Alliance Why? To advance medical knowledge and improve clinical care. How? By encouraging the widespread ability to address genomic and clinical data in an interoperable, secure, and trusted manner that preserves diversity of approach and application, and by enabling comparison of genetic variants and clinical features. Specifically: a global alliance is needed to bring together researchers, health care providers, funders, disease advocacy organizations, life science and technology companies, and informed citizens to enable, support, and promote the responsible sharing of genomic and clinical data.
16 A Way Forward: The Global Alliance Media Coverage across the World
17 A Way Forward: The Global Alliance Partners American Association for Cancer Research (US) American Society of Clinical Oncology (US) American Society of Human Genetics (US) Association for Molecular Pathology (US) A-T Children's Project (US) Beth Israel Deaconess Medical Center (US) BGI-Shenzhen (CN) Boston Children s Hospital (US) Brigham and Women's Hospital (US) Broad Institute of MIT and Harvard (US) California Institute of Technology (US) Canadian Cancer Society (CA) Canadian Institutes for Health Research (CA) Cancer Commons (US) Cancer Research UK (UK) Center for Genomic Regulation (ES) Centre for Comparative Genomics, Murdoch University (AU) Centre for the Advancement of Sustainable Medical Innovation (UK) Centro Nacional de Analisis Genomico (ES) Chinese Academy of Sciences (CN) Coalition of Heritable Disorders of Connective Tissue (US) Community Oncology Research Consortium (US) Dahlem Center for Genome Research and Medical Systems Biology, Max Planck Institute (DE) Dana-Farber Cancer Institute (US) ELIXIR (UK) EMBL- European Bioinformatics Institute (UK) European Molecular Biology Laboratory (DE) European Society of Human Genetics (AT) Genetic Alliance (US) Genetic Alliance UK (UK) Genome Canada (CA) Global Genes RARE Project (US) H3ABioNet Consortium (ZA) Howard Hughes Medical Institute (US) Human Genome Organization (SG) Human Variome Project International (AU) Huntington Society of Canada (CA) Institut National du Cancer (FR) Institute for Systems Biology (US) International Cancer Genome Consortium (CA) International Rare Diseases Research Consortium (FR) Johns Hopkins University School of Medicine (US) King s Health Partners (UK) Knight Cancer Institute, Oregon Health & Science University (US) Lund University (SE) Massachusetts Eye and Ear Infirmary (US) Massachusetts General Hospital (US) McGill University/Université McGill (CA) McLaughlin Centre, Faculty of Medicine, University of Toronto (CA) Memorial Sloan-Kettering Cancer Center (US) National Cancer Center (JP) National Cancer Institute (US) National Human Genome Research Institute (US) National Institute for Health and Welfare (FI) National Institute for Health Research (UK) National Institutes of Health (US) New York Genome Center (US) Ontario Institute for Cancer Research (CA) Ontario Personalized Medicine Network (CA) Partners HealthCare (US) P3G Public Population Project in Genomics and Society (CA) PHG Foundation (UK) PXE International (US) Queen's University Belfast (UK) RD-Connect (UK) RIKEN Center for Integrative Medical Sciences (JP) Sage Bionetworks (US) Samuel Lunenfeld Research Institute, Mount Sinai Hospital (CA) Simons Foundation (US) Spanish Institute of Bioinformatics (ES) Spanish National Cancer Research Center (ES) St. Jude Children's Research Hospital (US) Stanford University (US) Sunnybrook Health Sciences Centre (CA) SIB-Swiss Institute of Bioinformatics (CH) The Hospital for Sick Children (CA) The University of Cape Town (ZA) University Health Network (CA) University of California, Berkeley (US) University of California Health System (US) University of California, San Francisco (US) University of California, Santa Cruz (US) University of Chicago (US) University of Michigan (US) University of Oxford (UK) University of Texas M.D. Anderson Cancer Center (US) University of Toronto (CA) University of Waterloo (CA) Weill Cornell Medical College (US) Wellcome Trust Sanger Institute (UK) The Wellcome Trust (UK)
18 A Way Forward: The Global Alliance
20 ELSI 2.0 Building a Collaboratory A new project whose administrative hub is P 3 G. Mission: to accelerate the translation of ELSI research findings into practice and policy. Jane Kaye et al., ELSI 2.0 for Genomics and Society. Science 336, (2012).
21 P 3 G Mission An international not-for-profit corporation; Dedicated to the development and management of biobanks, research databases and other similar health and social research infrastructures; Through its tools, support and networks, help the international research community with effective strategies to promote the health of individuals, families and communities; Comprises more than 450 individual and institutional members
22 Research Programmes Maelstrom Research Programme (dir. I. Fortier) Paediatric Research Programme (dir. E. Clayton) CGP Policy Research Programme (dir. B.M. Knoppers) HARMONIZATION Research Partnership (ex. BioSHaRE.EU; Qc Harmonization Platform) P 3 G employees working with the harmonization team PAEDIATRICS Research/Services Partnership POLICY Research/Services Partnership IPAC International Policy interoperability and data Access Clearinghouse
23 P3G-IPAC Building an International Policy interoperability and data Access Clearinghouse
24 IPAC Structure C o l l a b o r a t o r s P3G Head Office Exec. Director Op. Director - Comm. Officer Adm. Assistant Domain Expert Research Assistant IPAC Coordinator Domain Expert Research Assistant Domain Expert Research Assistant International Advisory Board Document Coder Domain Expert Research Assistant Archivist ( ) ( )
25 IPAC International Advisory Board International Advisory Board Jane Kaye (UK) Ching-Li Hu (China) Jean McEwen (USA) Jantina de Vries (South Africa) John Wilbanks (USA) Nils Hoppe (Germany) Pedro Rondot Radío (Argentina) Sharon Terry (USA) Zakiya Al-Lamki (Oman-TBC) Ruth Chadwick (UK) Mats Hansson (Sweden) Ellen Wright Clayton (USA) Emmanuelle Rial-Sebbag (France) Kazuto Kato (Japan) Don Chalmers (Australia) Susan Wallace (UK)
27 Problems and Proposals: Ethics Harmonisation
28 Problems with the Current Ethics Oversight System Disproportionate fixation on individual risks See recent discussion in Rosamond Rhodes et al., De Minimis Risk: A Proposal for a New Category of Research Risk, American Journal of Bioethics (2011). Disregard of alternative bioethical lenses that are more suitable for genomics research and respectful of research participants in the modern era (e.g., citizenry and solidarity) Overly politicized & under transparent Ossified
29 Problems with the Current Ethics Oversight System Nuremberg mentality : all research projects face the same level of scrutiny. RECs are reluctant to publish their decisions, share decisions with other RECs, or defer to their colleagues in other institutions. RECs are quasi-judicial entities, yet lack transparent jurisprudence or published procedural norms.
30 Problems with the Current Ethics Oversight System Costly Fragmented Inefficient Inconsistent Most investigators expressed concerns that differing views of risk as well as logistical variations across IRBs discouraged multi-site research at a time when large samples are needed to advance science.
31 Ethics Harmonisation: Where to from Here? "Turn him to any cause of policy, The Gordian Knot of it he will unloose, Familiar as his garter" (Shakespeare, Henry V, Act 1 Scene ) Alexander cuts the Gordian Knot Jean-Simon Berthélemy ( )
32 Ethics Harmonisation: Where to from Here? Some countries have attempted to improve the status quo, but none at a global level. There should be gateways for researchers that ensure high standards and consistent application for noninterventional studies that test neither drugs nor devices, and that work toward the mutual recognition between countries of ethically equivalent approaches.
33 P 3 G 53 Studies Harmonisation Project Europe: 26 studies; 3,4 million participants Asia: 5 studies; 0,7 million participants North America: 17 studies; 2,5 million participants Australia: 5 studies; 0,3 million participants Fortier I, Doiron D, Little J, Ferretti V, L Heureux F, Stolk R, Knoppers BM, Hudson T, Burton PR on behalf of the International Harmonization Initiative: Is Rigorous Retrospective Harmonization Possible? Application of the DataSHaPER Approach across 53 Large Studies :5 Int J Epidemiol
34 Conclusion: A Safe Harbour Approach? In a world of Big Research and Big Data, Big Ethics is needed. View of Delft, Jan Vermeer, 1660
The collection, linking and use of data in biomedical research and health care: ethical issues Nuffield Council on Bioethics Professor Jonathan Montgomery (Chair) Professor Simon Caney Professor Bobbie
Policy Harmonization Through Collaboration: The Interstate Alliance on Stem Cell Research By Geoffrey P. Lomax, Dr.PH., Erik J. Forsberg, Ph.D., Dan Gincel, Ph.D., Debra S. Grega, Ph.D., Melissa J. Lopes,
Policy Brief: Protecting Privacy in Cloud-Based Genomic Research Version 1.0 July 21 st, 2015 Suggested Citation: Adrian Thorogood, Howard Simkevitz, Mark Phillips, Edward S Dove & Yann Joly, Policy Brief:
Options for for Strengthening Responsible Research and Innovation Research and and Innovation EUROPEAN COMMISSION Directorate-General for for Research and and Innovation Directorate B - B - European Research
CHILDREN AND FAMILIES EDUCATION AND THE ARTS ENERGY AND ENVIRONMENT HEALTH AND HEALTH CARE INFRASTRUCTURE AND TRANSPORTATION The RAND Corporation is a nonprofit institution that helps improve policy and
EUROPEAN COMMISSION Brussels, 2.7.2014 COM(2014) 442 final COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE
Big Data and Analytics: Seeking Foundations for Effective Privacy Guidance A Discussion Document February 2013 Introduction Analytics 1 promises to revolutionize business, science, research and education.
2011 CONSUMER U.S. INTELLECTUAL DATA PRIVACY PROPERTY ENFORCEMENT IN A NETWORKED COORDINATOR WORLD: COVER ANNUAL TITLE REPORT HERE ON A FRAMEWORK FOR PROTECTING PRIVACY INTELLECTUAL AND PROMOTING PROPERTY
Big data road map Foreword Rt Hon Earl Howe, Parliamentary Under Secretary for Quality, Department of Health Rt Hon David Willetts MP, Minister for Universities and Science, Department for Business, Innovation
BIG DATA Workshop 16 th European Health Forum Gastein REPORT - OCTOBER 2013 The Big Data Workshop was organised by the European Alliance for Personalised Medicine and supported by the Lithuanian Health
Embedding Privacy into the Design of EHRs to Enable Multiple Functionalities Win/Win March 2, 2012 Information and Privacy Commissioner, Ontario, Canada Ann Cavoukian, Ph.D. Information & Privacy Commissioner
Going the extra mile: Improving the nation s health and wellbeing through public involvement in research The final report and recommendations to the Director General Research and Development / Chief Medical
mhealth and the EU regulatory framework for medical devices 1 2 Introduction European healthcare systems face major challenges, including ageing populations and the growing incidence of chronic diseases,
New Data for Understanding the Human Condition: International Perspectives OECD Global Science Forum Report on Data and Research Infrastructure for the Social Sciences Data-driven and evidence-based research
Data for Individual Health Prepared for: Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. JSR-14-TASK-007 Prepared by: JASON The MITRE Corporation
ARTICLE PRIVACY AND SECURITY IN THE IMPLEMENTATION OF HEALTH INFORMATION TECHNOLOGY (ELECTRONIC HEALTH RECORDS): U.S. AND EU COMPARED JANINE HILLER PROFESSOR OF BUSINESS LAW PAMPLIN COLLEGE OF BUSINESS
CHAPTER 1.8 From Big Data to Big Social and Economic Opportunities: Which Policies Will Lead to Leveraging Data-Driven Innovation s Potential? PEDRO LESS ANDRADE JESS HEMERLY GABRIEL RECALDE PATRICK RYAN
Better Information for Improved Health: A Vision for Health System Use of Data in Canada June 2013 Prepared by the Canadian Institute for Health Information, in collaboration with Canada Health Infoway,
Umbilical Cord Blood Banking in Canada: Socio-Ethical and Legal Issues Margo Plant & Bartha Maria Knoppers* Promising discoveries about the lifesaving attributes of umbilical cord blood (UCB) stem cells
Health 2020 A European policy framework and strategy for the 21st century Abstract The 53 countries of the European Region approved a new value- and evidence-based health policy framework for the Region,
Big Data and Health Revolutionizing medicine and Public Health Report of the Big Data and Health Working Group 2013 Professor Alex Pentland, Dr Todd G Reid, and Dr Tracy Heibeck 3 WISH Big Data and Health
PALLIATIVE CARE FOR OLDER PEOPLE: BETTER PRACTICES FONDAZIONE MARUZZA LEFEBVRE D OVIDIO ONLUS WHO Collaborating Centre for Palliative Care and Older People Palliative care for older people: better practices
IT Roundtable October 23-24, 2014 Meeting Summary V2 12.23.14 Contents Background... 1 Need for Clinical Data in Clinical Research... 1 2013 Information Technology Roundtable White Paper... 1 2014 IT Roundtable
Revised March 2014 Data Protection Principles for the 21 st Century Revising the 1980 OECD Guidelines Fred H. Cate Distinguished Professor and C. Ben Dutton Professor of Law, Maurer School of Law, Indiana
Authored by: Cynthia Duggan Associate Director, Alzheimer's Disease and Dementia Initiative, The New York Academy of Sciences Drew Holzapfel Executive Director, The Global CEO Initiative on Alzheimer s
Working Paper 20 April 2014 WP 20 BUILDING BETTER HEALTH CARE Policy opportunities for Ontario Institute for Competitiveness & Prosperity The Institute for Competitiveness & Prosperity is an independent